Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

Core Insights - Praxis Precision Medicines, Inc. has appointed Dr. Orrin Devinsky as Head of Clinical Strategy, a newly created leadership role, reflecting the company's commitment to advancing its clinical strategy and global medical affairs [1][3] Group 1: Appointment and Role - Dr. Devinsky is a highly influential figure in epilepsy and clinical neuroscience, with over 40 years of experience and significant contributions to the development of transformative therapies [2] - In his new role, Dr. Devinsky will guide program architecture, evidence generation, and external scientific engagement as Praxis advances its late-stage portfolio toward commercialization [3] Group 2: Contributions and Achievements - Dr. Devinsky has been instrumental in pivotal clinical trials leading to the FDA approval of cannabidiol therapy for various severe epilepsy syndromes, marking a new therapeutic class for rare epilepsies [4] - His scientific contributions include over 500 peer-reviewed publications and 16 issued patents in areas such as epilepsy therapeutics and drug delivery [4] Group 3: Organizational Impact - Dr. Devinsky has founded or co-founded several impactful organizations in the epilepsy community, including FACES and the North American SUDEP Registry, enhancing the understanding of epilepsy-related mortality [5] - His career has been recognized with prestigious awards, including the American Epilepsy Society J. Kiffin Penry Award and the 2025 Epilepsy Foundation Lifetime Accelerator Award [5] Group 4: Company Vision - Dr. Devinsky expressed confidence in Praxis's scientific rigor and long-term vision, highlighting the company's comprehensive precision-based pipelines for epilepsy therapies [6] - Praxis is focused on translating genetic insights into therapies for CNS disorders, utilizing proprietary platforms for drug development [7]